Pharnext, CMT Association Partner on CMT1A Biomarkers to Support Phase 3 Study
Pharnext and the Charcot-Marie-Tooth Association (CMTA) have partnered to find new biomarkers associated with Charcot-Marie-Tooth disease type 1A (CMT1A), the most common subtype of the disease, according to a press release. Its goal is to identify and validate CMT1A biomarkers that signal responses to treatment, and…